310 related articles for article (PubMed ID: 8645243)
1. Inhibition of Borrelia burgdorferi-bound fibrinolytic enzymes by alpha2-antiplasmin, PAI-1 and PAI-2.
Perides G; Noring R; Klempner MS
Biochem Biophys Res Commun; 1996 Feb; 219(3):690-5. PubMed ID: 8645243
[TBL] [Abstract][Full Text] [Related]
2. The roles of alpha 2-antiplasmin and plasminogen activator inhibitor 1 (PAI-1) in the inhibition of clot lysis.
Robbie LA; Booth NA; Croll AM; Bennett B
Thromb Haemost; 1993 Aug; 70(2):301-6. PubMed ID: 8236139
[TBL] [Abstract][Full Text] [Related]
3. The Role of Fibrinolytic System in Health and Disease.
Kwaan HC
Int J Mol Sci; 2022 May; 23(9):. PubMed ID: 35563651
[TBL] [Abstract][Full Text] [Related]
4. Reciprocal upregulation of urokinase plasminogen activator and its inhibitor, PAI-2, by Borrelia burgdorferi affects bacterial penetration and host-inflammatory response.
Haile WB; Coleman JL; Benach JL
Cell Microbiol; 2006 Aug; 8(8):1349-60. PubMed ID: 16882037
[TBL] [Abstract][Full Text] [Related]
5. Plasminogen activators (t-PA and u-PA) and plasminogen activators inhibitors (PAI-1 and PAI-2) in some myeloproliferative syndromes.
Rość D; Kremplewska-Nalezyta E; Gadomska G; Zastawna E; Michalski A; Drewniak W
Med Sci Monit; 2000; 6(4):684-91. PubMed ID: 11208392
[TBL] [Abstract][Full Text] [Related]
6. Expression of urokinase, plasminogen activator inhibitors and urokinase receptor in pregnant rhesus monkey uterus during early placentation.
Feng Q; Liu Y; Liu K; Byrne S; Liu G; Wang X; Li Z; Ockleford CD
Placenta; 2000; 21(2-3):184-93. PubMed ID: 10736241
[TBL] [Abstract][Full Text] [Related]
7. Kinetic analysis of plasminogen activator inhibitor type-2: urokinase complex formation and subsequent internalisation by carcinoma cell lines.
Al-Ejeh F; Croucher D; Ranson M
Exp Cell Res; 2004 Jul; 297(1):259-71. PubMed ID: 15194441
[TBL] [Abstract][Full Text] [Related]
8. Regulated localization confers multiple functions on the protease urokinase plasminogen activator.
Wells JM; Strickland S
J Cell Physiol; 1997 May; 171(2):217-25. PubMed ID: 9130470
[TBL] [Abstract][Full Text] [Related]
9. Effects of alpha2-plasmin inhibitor on fibrin clot lysis. Its comparison with alpha2-macroglobulin.
Aoki N; Moroi M; Tachiya K
Thromb Haemost; 1978 Feb; 39(1):22-31. PubMed ID: 77050
[TBL] [Abstract][Full Text] [Related]
10. Plasminogen activator inhibitor-1 represses integrin- and vitronectin-mediated cell migration independently of its function as an inhibitor of plasminogen activation.
Kjøller L; Kanse SM; Kirkegaard T; Rodenburg KW; Rønne E; Goodman SL; Preissner KT; Ossowski L; Andreasen PA
Exp Cell Res; 1997 May; 232(2):420-9. PubMed ID: 9168821
[TBL] [Abstract][Full Text] [Related]
11. Binding and activation of plasminogen at the surface of human keratinocytes.
Reinartz J; Batrla R; Boukamp P; Fusenig N; Kramer MD
Exp Cell Res; 1993 Sep; 208(1):197-208. PubMed ID: 8359216
[TBL] [Abstract][Full Text] [Related]
12. Relationship of urokinase type plasminogen activator, plasminogen activator inhibitor type 1 and activated protein C in fibrinolysis of human placenta.
Moniwa N
Pol J Pharmacol; 1996; 48(2):215-20. PubMed ID: 9112654
[TBL] [Abstract][Full Text] [Related]
13. Monocyte-macrophage release of IL-1 is inhibited by type-1 plasminogen activator inhibitors.
Robson SC; Saunders R; Kirsch RE
J Clin Lab Immunol; 1990 Oct; 33(2):83-90. PubMed ID: 1967070
[TBL] [Abstract][Full Text] [Related]
14. The behavior of alpha2-plasmin inhibitor in fibrinolytic states.
Aoki N; Moroi M; Matsuda M; Tachiya K
J Clin Invest; 1977 Aug; 60(2):361-9. PubMed ID: 68962
[TBL] [Abstract][Full Text] [Related]
15. Differential inhibition of soluble and cell surface receptor-bound single-chain urokinase by plasminogen activator inhibitor type 2. A potential regulatory mechanism.
Schwartz BS
J Biol Chem; 1994 Mar; 269(11):8319-23. PubMed ID: 7907591
[TBL] [Abstract][Full Text] [Related]
16. Enhanced fibrinolytic potential in mice with combined homozygous deficiency of alpha2-antiplasmin and PAI-1.
Dewerchin M; Collen D; Lijnen HR
Thromb Haemost; 2001 Aug; 86(2):640-6. PubMed ID: 11522016
[TBL] [Abstract][Full Text] [Related]
17. Matrix metalloproteinases and cellular fibrinolytic activity.
Lijnen HR
Biochemistry (Mosc); 2002 Jan; 67(1):92-8. PubMed ID: 11841344
[TBL] [Abstract][Full Text] [Related]
18. Binding of human plasminogen and urokinase-type plasminogen activator to the Lyme disease spirochete, Borrelia burgdorferi.
Klempner MS; Noring R; Epstein MP; McCloud B; Hu R; Limentani SA; Rogers RA
J Infect Dis; 1995 May; 171(5):1258-65. PubMed ID: 7751701
[TBL] [Abstract][Full Text] [Related]
19. Expression of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor and plasminogen activator inhibitors in patients with renal cell carcinoma: correlation with tumor associated macrophage and prognosis.
Ohba K; Miyata Y; Kanda S; Koga S; Hayashi T; Kanetake H
J Urol; 2005 Aug; 174(2):461-5. PubMed ID: 16006865
[TBL] [Abstract][Full Text] [Related]
20. Effects of long-term erythropoietin therapy on fibrinolytic system in haemodialyzed patients.
Pawlak K; Pawlak D; Mysliwiec M
Thromb Res; 2008; 121(6):787-91. PubMed ID: 17869326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]